Lou Bock

Louis Bock Venture Partner

Lou joined Santé Ventures as Venture Partner in 2014. Prior to joining Santé, Lou was a Partner and Co-Founder of Scale Venture Partners from 1997-2014. He was a member of the healthcare team and built the firm’s biotech practice. Lou joined Scale in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales.  Prior to Gilead, he was a research associate at Genentech.  Lou has been involved with life science companies that have completed 8 IPOs and 4 acquisitions.  The current public companies have a market cap in excess of $6B.  A number of his portfolio companies have received FDA approvals and are treating patients for important indications including Adcetris for the treatment of Hodgkin’s Lymphoma, Xenazine for the treatment of Huntington’s disease and Rayos for the treatment of rheumatoid arthritis.  Lou holds an M.B.A. in Finance from California State University, San Francisco and a B.S. in Biology from California State University, Chico.

News
December 5, 2018 Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors
Read More
November 2, 2018 HNI Healthcare Acquires Martin Healthcare Group to Expand Footprint
Read More